Comprehensive risk profiling and long-term cardiovascular toxicity in HER2-positive breast cancer patients treated with trastuzumab
Cardiotoxicity remains a major concern in long-term trastuzumab therapy. This single-center study highlights the critical importance of integrating baseline risk stratification with serial monitoring of advanced echocardiographic parameters like LVGLS and sensitive biomarkers like hs-cTnI. Our comprehensive predictive model offers a powerful tool for early identification of at-risk patients, guiding personalized surveillance and facilitating timely implementation of cardioprotective strategies to mitigate the risk of irreversible cardiac damage in this patient population.
Authors
- Xueli Wang (ORCID: https://orcid.org/0009-0001-0033-636X)
- Chunlin Wu (ORCID: https://orcid.org/0000-0002-1333-5454)
- Xiaoke Shang (ORCID: https://orcid.org/0009-0004-3915-598X)
- Meiying Wang (ORCID: https://orcid.org/0000-0003-3563-9974)
- Min Xia (ORCID: https://orcid.org/0000-0002-1093-5008)
- Song Chen (ORCID: https://orcid.org/0000-0001-5372-9231)
- Xiong Zhang (ORCID: https://orcid.org/0000-0002-9214-396X)
- Ming Sun (ORCID: https://orcid.org/0000-0002-1173-2288)
- Shanshan Ding (ORCID: https://orcid.org/0000-0003-3776-4074)
- Changdong Zhang (ORCID: https://orcid.org/0009-0007-5417-8305)
- Jia Wang (ORCID: https://orcid.org/0000-0002-2330-8505)
Institutions
- Wuhan Union Hospital (CN)
- Wuhan Sixth Hospital (CN)
- Union Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.3389/fonc.2025.1684289
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00